Compare Cadila Healthcare with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs TORRENT PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE TORRENT PHARMA CADILA HEALTHCARE/
TORRENT PHARMA
 
P/E (TTM) x 34.7 38.5 90.1% View Chart
P/BV x 6.1 9.8 62.4% View Chart
Dividend Yield % 0.6 0.6 90.8%  

Financials

 CADILA HEALTHCARE   TORRENT PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
TORRENT PHARMA
Mar-19
CADILA HEALTHCARE/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs3521,964 17.9%   
Low Rs2071,245 16.6%   
Sales per share (Unadj.) Rs139.2453.4 30.7%  
Earnings per share (Unadj.) Rs11.825.8 45.6%  
Cash flow per share (Unadj.) Rs18.662.3 29.8%  
Dividends per share (Unadj.) Rs3.5017.00 20.6%  
Dividend yield (eoy) %1.31.1 118.2%  
Book value per share (Unadj.) Rs101.4279.2 36.3%  
Shares outstanding (eoy) m1,023.74169.22 605.0%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x2.03.5 56.7%   
Avg P/E ratio x23.762.2 38.2%  
P/CF ratio (eoy) x15.025.8 58.4%  
Price / Book Value ratio x2.85.7 48.0%  
Dividend payout %29.865.9 45.1%   
Avg Mkt Cap Rs m286,033271,513 105.3%   
No. of employees `00013.413.6 98.6%   
Total wages/salary Rs m24,14514,038 172.0%   
Avg. sales/employee Rs Th10,632.75,642.6 188.4%   
Avg. wages/employee Rs Th1,801.21,032.4 174.5%   
Avg. net profit/employee Rs Th898.5320.9 280.0%   
INCOME DATA
Net Sales Rs m142,53176,728 185.8%  
Other income Rs m1,139571 199.6%   
Total revenues Rs m143,67077,299 185.9%   
Gross profit Rs m24,19819,831 122.0%  
Depreciation Rs m6,9656,177 112.8%   
Interest Rs m3,4185,038 67.9%   
Profit before tax Rs m14,9549,187 162.8%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,570 0.0%   
Tax Rs m3,1981,254 255.1%   
Profit after tax Rs m12,0444,363 276.0%  
Gross profit margin %17.025.8 65.7%  
Effective tax rate %21.413.6 156.7%   
Net profit margin %8.55.7 148.6%  
BALANCE SHEET DATA
Current assets Rs m87,15450,375 173.0%   
Current liabilities Rs m82,69451,653 160.1%   
Net working cap to sales %3.1-1.7 -187.9%  
Current ratio x1.11.0 108.1%  
Inventory Days Days7192 77.6%  
Debtors Days Days9468 137.4%  
Net fixed assets Rs m133,23683,648 159.3%   
Share capital Rs m1,024846 121.0%   
"Free" reserves Rs m102,73346,397 221.4%   
Net worth Rs m103,75747,244 219.6%   
Long term debt Rs m32,14639,129 82.2%   
Total assets Rs m236,866141,209 167.7%  
Interest coverage x5.42.8 190.4%   
Debt to equity ratio x0.30.8 37.4%  
Sales to assets ratio x0.60.5 110.7%   
Return on assets %6.56.7 98.1%  
Return on equity %11.69.2 125.7%  
Return on capital %13.712.3 111.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52,75222,103 238.7%   
Fx outflow Rs m14,5045,522 262.7%   
Net fx Rs m38,24816,581 230.7%   
CASH FLOW
From Operations Rs m25,05417,981 139.3%  
From Investments Rs m-10,123-2,413 419.6%  
From Financial Activity Rs m-10,942-13,145 83.2%  
Net Cashflow Rs m3,9892,380 167.6%  

Share Holding

Indian Promoters % 74.8 71.5 104.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 7.0 118.2%  
FIIs % 5.9 12.6 46.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 8.8 125.0%  
Shareholders   44,069 26,511 166.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   ORCHID PHARMA  CIPLA  ABBOTT INDIA  SUVEN LIFE SCIENCES  WYETH  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


May 14, 2021 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS